SCHEMBL4941108

SCHEMBL4941108

CC(=O)NS(=O)(=O)c1ccc(F)c2nonc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
OPRK1 P41145 1/20 0.41
NLRP3 Q96P20 6/20 0.40
POLB P06746 3/20 0.40
RORA P35398 1/20 0.38
RORC P51449 1/20 0.38
NR1H2 P55055 1/20 0.38
DHFR P00374 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.35
TP53 P04637 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4942470 0.82 RORA (0.40) CHRM1KMT2ANLRP3POLBRORA
SCHEMBL1271332 0.76 TET2 (0.46) CHRM1KMT2AMEN1NLRP3POLB
Ammonia Solution, Strong SCHEMBL591415 0.74 TET2 (0.45) CHRM1KMT2AMEN1NLRP3POLB
SCHEMBL6397094 0.74 ALDH1A1 (0.54) KMT2AMEN1MAPTPOLBRORA
SCHEMBL2530974 0.74 POLB (0.40) CHRM1KMT2AMEN1POLBRORA
SCHEMBL22734625 0.73 KMT2A (0.38) CHRM1KMT2ANLRP3POLBRORA
SCHEMBL571688 0.73 TET2 (0.46) CHRM1KMT2AMEN1MAPTPOLB
SCHEMBL10693669 0.73 POLB (0.37) CHRM1KMT2AMEN1NLRP3POLB
Trimethylammonium SCHEMBL22734573 0.72 KMT2A (0.37) CHRM1KMT2ANLRP3POLBRORA
Hydrochloric Acid SCHEMBL22734577 0.72 KMT2A (0.37) CHRM1KMT2APOLBRORARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2019-04-30 US disclosed
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH 2018-05-17 US disclosed
EP-1705482-B1 METHOD OF DETECTION, SEPARATION AND IDENTIFICATION FOR EXPRESSED TRACE PROTEIN/PEPTIDE IMAI KAZUHIRO (JP) 2017-09-27 EP disclosed
WO-2016187050-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2016-11-24 WO disclosed
US-9188857-B2 Resist polymer, process for production thereof, resist composition, and process for production of substrates with patterns thereon MITSUBISHI RAYON CO., LTD. (JP) 2015-11-17 US disclosed
US-8796037-B2 Method of detection, separation and identification for expressed trace protein/peptide IMAI KAZUHIRO (JP) 2014-08-05 US disclosed
US-20130252181-A1 RESIST POLYMER, PROCESS FOR PRODUCTION THEREOF, RESIST COMPOSITION, AND PROCESS FOR PRODUCTION OF SUBSTRATES WITH PATTERNS THEREON MITSUBISHI RAYON CO., LTD. (JP) 2013-09-26 US disclosed
US-8476401-B2 Resist polymer, process for production thereof, resist composition, and process for production of substrated with patterns thereon MITSUBISHI RAYON CO., LTD. (JP) 2013-07-02 US disclosed
US-20080280316-A1 Mass spectrometry; liquid chromatography; automatic fractionation IMAI KAZUHIRO 2008-11-13 US disclosed
US-20080032241-A1 Resist Polymer, Process For Production Thereof, Resist Composition, And Process For Production Of Substrated With Patterns Thereon MITSUBISHI RAYON CO., LTD. (JP) 2008-02-07 US disclosed
EP-1705482-A2 METHOD OF DETECTION, SEPARATION AND IDENTIFICATION FOR EXPRESSED TRACE PROTEIN/PEPTIDE Imai, Kazuhiro (JP) 2006-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS CTNNB1, CTNNBL1, WNT3A CHRM1 4818/4885KMT2A 4263/4885MEN1 3834/4885
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions CTNNB1, CTNNBL1, WNT3A CHRM1 4843/4885KMT2A 4190/4885MEN1 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.